Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
BackgroundBisphosphonates are contraindicated in patients with stage 4+ chronic kidney disease. However, they are widely used to prevent fragility fractures in stage 3 chronic kidney disease, despite a lack of good-quality data on their effects.
ObjectivesThe aims of each work package were as follows. Work package 1: to study the relationship between bisphosphonate use and chronic kidney disease progression. Work package 2: to study the assoc... Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Queen’s Printer and Controller of HMSO
- Copyright date:
- Rights statement:
- © Queen’s Printer and Controller of HMSO 2021. This work was produced by Robinson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
If you are the owner of this record, you can report an update to it here: Report update to this record